Asked by: Tom Morrison (Liberal Democrat - Cheadle)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure a strategic approach to biomedical research into myalgic encephalomyelitis and chronic fatigue syndrome.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR).
We are committed to working with the myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), community to identify and address barriers to research, with the ambition of supporting more research and capacity-building programmes. As part of our approach, together with the Medical Research Council (MRC), we are actively exploring next steps in ME/CFS research, as outlined in the ME/CFS Final Delivery Plan. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical interventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions research, including ME/CFS and long COVID, in November to stimulate further research in this field.
We have previously discussed ringfenced funding with the ME/CFS community during the development of the Final Delivery Plan for ME/CFS, as well as at subsequent meetings and roundtables on ME/CFS and long COVID. However, this is not usual practice for research funders as applications in all areas should compete for the funding available to uphold transparency and accountability. The NIHR welcomes funding applications for research into any aspect of human health and care, including ME/CFS. Our position is that welcoming applications on ME/CFS to all programmes enables maximum flexibility both in terms of the amount of research funding and the type of research which can be funded.
There has been no specific comparative review on the level of funding for research into ME/CFS compared to other illnesses. The Department invests over £1.6 billion each year on research through the NIHR, including on ME/CFS. Research funding is available, and applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Tom Morrison (Liberal Democrat - Cheadle)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make a comparative review into the adequacy of the level of funding for research into myalgic encephalomyelitis compared to other illnesses.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR).
We are committed to working with the myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), community to identify and address barriers to research, with the ambition of supporting more research and capacity-building programmes. As part of our approach, together with the Medical Research Council (MRC), we are actively exploring next steps in ME/CFS research, as outlined in the ME/CFS Final Delivery Plan. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical interventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions research, including ME/CFS and long COVID, in November to stimulate further research in this field.
We have previously discussed ringfenced funding with the ME/CFS community during the development of the Final Delivery Plan for ME/CFS, as well as at subsequent meetings and roundtables on ME/CFS and long COVID. However, this is not usual practice for research funders as applications in all areas should compete for the funding available to uphold transparency and accountability. The NIHR welcomes funding applications for research into any aspect of human health and care, including ME/CFS. Our position is that welcoming applications on ME/CFS to all programmes enables maximum flexibility both in terms of the amount of research funding and the type of research which can be funded.
There has been no specific comparative review on the level of funding for research into ME/CFS compared to other illnesses. The Department invests over £1.6 billion each year on research through the NIHR, including on ME/CFS. Research funding is available, and applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Adam Dance (Liberal Democrat - Yeovil)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he is taking steps to establish a specialised service for people with very severe myalgic encephalomyelitis or chronic fatigue symptom in Yeovil constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We published the final myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), delivery plan on 22 July, which focuses on boosting research, improving attitudes and education, and bettering the lives of people with this debilitating disease.
The commissioning of ME/CFS services is the responsibility of local integrated care boards (ICBs), including the NHS Somerset ICB, which covers the Yeovil constituency, based on their local population. The ME/CFS final delivery plan includes an action for the Department and NHS England to explore whether a specialised service should be prescribed by my Rt. Hon. Friend, the Secretary of State for Health and Social Care, for very severe ME/CFS.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, if he will hold discussions with the Secretary of State fo Health and Social Care on the potential merits of funding a research hub to (a) coordinate research and (b) support early-career researchers working on ME and Chronic Fatigue Syndrome.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
UK Research and Innovation (UKRI) and the National Institute for Health and Care Research (NIHR) work closely together to coordinate research into Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Extensive support is provided to early-career researchers through the NIHR Academy and NIHR Infrastructure.
ME/CFS is a priority area for UKRI’s Medical Research Council (MRC) and it has committed over £4,460,000 to ME/CFS research since 2020. NIHR has also committed approximately £3.7 million to this area across the 2019/20-2023/24 financial years.
MRC recently awarded funding to PRIME, a £800,000 partnership to build new research infrastructure for ME/CFS research. PRIME will establish new research collaborations, bringing together researchers and private sector partners, to investigate the genetics, biomarkers and disease mechanisms of ME/CFS.
Asked by: Mary Glindon (Labour - Newcastle upon Tyne East and Wallsend)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 July 2025 to Question 62460 on Chronic Fatigue Syndrome: Health Services, whether a date has been set for the showcase event for post-acute infection conditions.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
A provisional date of 6 November 2025 has been set for the showcase event for post-acute infection conditions. The event looks to encourage researchers to join the myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), and long COVID research field, to enable new collaborations across specialties and disciplines to stimulate further vital research.
Asked by: Anna Gelderd (Labour - South East Cornwall)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to allocate (a) new and (b) ring-fenced funding to support the implementation of the Final Delivery Plan for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, published in July 2025.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We recognise the negative impact that myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has on patients and their loved ones, and also the cost to health and care services and the wider economy through, for example, loss of work and an increased benefits bill. We, therefore, recently published the ME/CFS final delivery plan, which focuses on boosting research, improving attitudes and education, and bettering the lives of people with this debilitating disease.
There are currently no plans to allocate new or ring-fenced funding specifically to support the implementation of the ME/CFS final delivery plan. However, we continue to commission research on ME/CFS services across the United Kingdom, focussing on the most severely affected. The plan includes increased funding for research, awarded through the National Institute for Health and Care Research, into how existing medicines can be used for post-viral conditions, including ME/CFS. Additionally, there are always opportunities for researchers to bid for and secure research funding for ME/CFS through our open research funding calls.
Asked by: Tom Morrison (Liberal Democrat - Cheadle)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made a recent estimate of the potential impact of Myalgic encephalomyelitis on the economy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We recognise the negative impact that myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has on patients and their loved ones, and also the cost to health and care services and the wider economy through, for example, loss of work and an increased benefits bill. We, therefore, recently published the ME/CFS final delivery plan, which focuses on boosting research, improving attitudes and education, and bettering the lives of people with this debilitating disease.
There are currently no plans to allocate new or ring-fenced funding specifically to support the implementation of the ME/CFS final delivery plan. However, we continue to commission research on ME/CFS services across the United Kingdom, focussing on the most severely affected. The plan includes increased funding for research, awarded through the National Institute for Health and Care Research, into how existing medicines can be used for post-viral conditions, including ME/CFS. Additionally, there are always opportunities for researchers to bid for and secure research funding for ME/CFS through our open research funding calls.
Asked by: Bobby Dean (Liberal Democrat - Carshalton and Wallington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that referrals for ME/CFS are not rejected solely on the basis of a long covid diagnosis being mentioned in GP notes.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We published the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Final Delivery Plan on 22 July 2025. The plan focuses on boosting research, improving attitudes and education, and bettering the lives of people with this debilitating disease.
Within the ME/CFS Final Delivery Plan’s actions, NHS England will co-design resources, including a template specification for systems to improve services for mild and moderate ME/CFS. Additionally, the Department of Health and Social Care, with NHS England, will explore whether a specialised service should be prescribed by the Secretary of State for Health and Social Care for very severe ME/CFS.
The template specification for mild and moderate ME/CFS will be developed nationally through engagement with stakeholders, drawing on local expertise and models, and existing evidence.
In order to improve awareness and understanding of ME/CFS amongst healthcare professionals, the Department is working with NHS England to develop an e-learning programme on ME/CFS, with the aim of supporting staff to be able to provide better care and improve patient outcomes.
Commissioning of post-viral services is the responsibility of local integrated care boards (ICBs) and the output of the above engagement aims to support ICBs with their local commissioning decisions based on their local population needs.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) encourage research on and (b) support the development of (i) strategic partnerships and (ii) research infrastructure for ME and Chronic Fatigue Syndrome.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health and care, including post-acute infection condition such as myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), for which research funding is available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality, rather than designating an amount of funding for a particular condition. Welcoming applications on ME/CFS and other post-acute infection conditions to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.
The NIHR Academy offers extensive support for early-career researchers through various fellowships, training awards, and mentoring structures. For instance, through the INSIGHT Programme, they work with universities to fund research masters studentships and to attract students into research. Through Academic Clinical Fellowships, for doctors and dentists, and Predoctoral Academic Fellowships, for other health professionals, the NIHR Academy supports healthcare practitioners in integrating research with clinical practice.
Together with the Medical Research Council (MRC), which is part of UK Research and Innovation, we are actively exploring next steps in ME/CFS research, as outlined in the ME/CFS final delivery plan. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical inventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions research, including for ME/CFS and long COVID, later this year to stimulate further research in this field.
Asked by: Jo Platt (Labour (Co-op) - Leigh and Atherton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding his Department plans to allocate for research on ME and Chronic Fatigue Syndrome in the next (a) year and (b) five years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health and care, including post-acute infection condition such as myalgic encephalomyelitis, also known as chronic fatigue syndrome (ME/CFS), for which research funding is available. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality, rather than designating an amount of funding for a particular condition. Welcoming applications on ME/CFS and other post-acute infection conditions to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.
The NIHR Academy offers extensive support for early-career researchers through various fellowships, training awards, and mentoring structures. For instance, through the INSIGHT Programme, they work with universities to fund research masters studentships and to attract students into research. Through Academic Clinical Fellowships, for doctors and dentists, and Predoctoral Academic Fellowships, for other health professionals, the NIHR Academy supports healthcare practitioners in integrating research with clinical practice.
Together with the Medical Research Council (MRC), which is part of UK Research and Innovation, we are actively exploring next steps in ME/CFS research, as outlined in the ME/CFS final delivery plan. This includes a new funding opportunity for a development award focussed on evaluating repurposed pharmaceutical inventions for post-acute infection syndromes and associated conditions, including ME/CFS. This funding opportunity is one component of our approach to improve evidence around the diagnosis, management, and treatment of post-acute infection conditions, including ME/CFS. We are also planning an NIHR and MRC hosted showcase event for post-acute infection conditions research, including for ME/CFS and long COVID, later this year to stimulate further research in this field.